The FDA-cleared Optecure demineralized bone matrix [Image courtesy of RTI Surgical]
RTI Surgical announced a long-term agreement with Exactech for the development and supply of biologic bone substitutes.
The deal, announced today, includes RTI Surgical acquiring Exactech’s FDA-cleared Optecure demineralized bone matrix, used as a bone graft extender in the spine, pelvis, and extremities. RTI Surgical officials think Optecure will complement their portfolio of bone graft substitutes. RTI Surgical offers a portfolio of tissue-based, synthetic and metal implants to OEM customers.